截至2026年2月25日收盘，骏创科技（920533）报收于29.3元，较前一交易日下跌2.63%，最新总市值为 38.31亿元。该股当日开盘29.97元，最高30.07元，最低29.05元，成交额达1.04亿元，换手率为4.88%。 《2025年年度业绩快报公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 骏创科技于2026年2月25日披露《2025年年度业绩快报公告》。公告显示，公司2025年实现营业收入 697,666,245.08元，同比下降7.59%；利润总额39,007,824.61元，同比下降30.64%；归属于上市公司股东 的净利润为35,158,787.49元，同比下降31.27%；扣除非经常性损益后的净利润同比下降38.13%。公告指 出，业绩变动主要原因为下游客户订单减少、新客户放量周期较长导致收入下滑，以及人民币兑美元汇 率走强带来汇兑损失、利息收入减少致财务费用上升。报告期末，公司总资产同比增长11.17%，所有 者权益增长4.46%。 最新公告列表 ...

证券日报网讯2月25日，骏创科技发布2025年年度业绩快报公告称，公司2025年实现营业收入 697666245.08元，同比下降7.59%；归属于上市公司股东的净利润35158787.49元，同比下降31.27%。 ...

骏 创科技公告，预计公司实现营业收入6.98亿元，较上年同期减少7.59%；预计公司利润总额3900.78万 元，较上年同期减少30.64%；归属于上市公司股东的净利润为3515.88万元，较上年同期减少31.27%； 归属于上市公司股东的扣除非经营性损益的净利润为3183.71万元，较上年同期减少38.13%；基本每股 收益为0.27元，较上年同期减少31.18%。 ...

（记者 胡玲） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前核实。据此操作，风险自担。 每日经济新闻 每经讯，2026年2月6日，北交所上市公司骏创科技（920533，收盘价：27.95元）发生一笔大宗交易，成交价20元/股，成交数量 30万股，成交金额600万元，折价28.44%。买入营业部是华安证券股份有限公司铜陵淮河路营业部，卖出营业部是中信建投证券 股份有限公司昆山长江中路证券营业部。 ...

Group 1 - The company, JunChuang Technology, announced the approval of adjustments to its 2025 stock option incentive plan during the 17th meeting of its fourth board of directors [2] - The company also approved the proposal for the initial grant of stock options to the incentive targets under the 2025 stock option incentive plan [2]

Group 1 - The company, JunChuang Technology, announced that its fourth board meeting's sixteenth session approved multiple proposals, including a significant resolution regarding the company's operations [2]

Group 1 - The company, JunChuang Technology, announced that it will hold the second extraordinary general meeting of shareholders for the year 2025 on December 31, 2025, at 14:00 [1]

Group 1 - The Beizheng 50 Index has dropped over 3% [1] - Among the constituent stocks, Jun Chuang Technology has fallen over 6% [1] - Yun Xingyu, Shuguang Shuchuang, and Tianma New Materials have all decreased by over 5% [1]

Investment Rating - The report indicates a strong rebound in the North Exchange, with a focus on the technology growth sector, particularly semiconductors and robotics, which are seen as core investment themes [4][9]. Core Insights - The North Exchange A-shares trading volume reached 20.69 billion yuan on September 24, a decrease of 3.72 billion yuan from the previous trading day, while the North Exchange 50 Index closed at 1578.92, up 2.03% [2][9]. - The North Exchange specialized and innovative index closed at 2762.51, increasing by 2.66% [2][9]. - Among the 276 companies listed on the North Exchange, 236 saw their stock prices rise, 2 remained flat, and 38 experienced declines [2][16]. Summary by Sections Market Review - On September 24, the North Exchange A-shares trading volume was 20.69 billion yuan, down from the previous day by 3.72 billion yuan [2][9]. - The North Exchange 50 Index increased by 2.03%, with a PE_TTM of 74.04 [2][9]. - The specialized and innovative index rose by 2.66% [2][9]. - The top five gainers included Henghe Co. (30.0%), Meizhigao (10.6%), Kaide Quartz (9.9%), Tiangang Co. (8.9%), and Yuanhang Precision (8.3%) [2][16]. - The top five decliners were Anhui Phoenix (-4.4%), Hongzhi Technology (-3.6%), Rongyi Precision (-3.0%), Wantong Hydraulic (-2.9%), and Tianma New Materials (-2.7%) [2][16]. Important News - Eight departments issued guidelines to promote digital consumption, proposing 14 tasks across four areas to enhance the digital consumption ecosystem [3][19]. - The "Vehicle-Road-Cloud Integration" pilot city construction is accelerating, with various cities, including Beijing and Haikou, advancing related projects [3][20]. Key Company Announcements - Kexin New Materials announced the acquisition of a utility model patent for a fixed device for transporting new energy crucibles [3][21]. - Xici Technology plans to invest up to 160 million yuan of idle funds in safe financial products [3][21].

Core Viewpoint - The article emphasizes the emergence of a new paradigm in China's economy, termed the "new new three samples," which includes robotics, artificial intelligence (AI), and innovative pharmaceuticals, as key drivers for high-quality economic development and a shift from traditional growth models to technology-led advancements [1][4][29]. Robotics Sector - The robotics sector has seen significant market capitalization growth, with companies like Huichuan Technology exceeding 200 billion yuan and several stocks doubling in price within the year [2][13]. - The market for industrial robots in China is projected to reach 302,000 units in 2024, maintaining its position as the largest industrial robot market globally [30]. - Key challenges include reliance on imported high-end servo motors and precision components, which need to be addressed to enhance domestic capabilities [33]. Artificial Intelligence Sector - The AI sector is characterized by a large number of high-value companies, with six firms exceeding a market cap of 100 billion yuan, including Cambricon and Hikvision [19]. - The demand for AI capabilities has surged, particularly in large model applications, leading to significant revenue growth for companies like Industrial Fulian and Cambricon, with year-on-year increases of 35.58% and 4347.82%, respectively [20]. - The sector is supported by national policies aimed at integrating AI into various industries, with a comprehensive action plan released to enhance AI's role in economic development [22]. Innovative Pharmaceuticals Sector - The innovative pharmaceuticals sector is represented by major players like Heng Rui Medicine, which is nearing a market cap of 500 billion yuan, and BeiGene, which recently achieved profitability [24][28]. - Recent policy measures have been introduced to support the development of innovative drugs, including streamlined approval processes and enhanced reimbursement mechanisms [27]. - The sector is witnessing a shift from loss-making to profitability, with companies like BeiGene demonstrating the commercial viability of innovative drug models [28]. Strategic Importance - The "new new three samples" signify a transition from scale-driven manufacturing to technology-driven innovation, crucial for enhancing China's global competitiveness and economic resilience [7][9][31]. - The collaboration among robotics, AI, and innovative pharmaceuticals creates a synergistic effect that strengthens overall productivity and fosters new business models [8][31]. - Addressing the "bottleneck" issues in these sectors is essential for sustaining growth and achieving leadership in global technology competition [32][33]. Policy Recommendations - To enhance competitiveness, policies should focus on data openness, regulatory reforms, and infrastructure development to support AI and innovative pharmaceuticals [35][38]. - Establishing a robust talent pipeline and fostering interdisciplinary education will be critical for sustaining innovation in these sectors [37][38]. - Encouraging public-private partnerships and international collaboration will further strengthen China's position in the global market [39].